ArticleScience advances2025
Mitochondria-localized photocatalyst of biomimetic organic semiconductor nanoparticles for NIR-activatable photocatalytic immunotherapy.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Irreversible NADH Cleavage by a Mitochondria-Targeted Metal-Free Photoredox Sensitizer with Activity in Cancer Cells.ACS medicinal chemistry letters · 2026Article
- A single-molecule prodrug synergistically suppresses MYC-amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy.Smart molecules : open access · 2026Article
- Article
- Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.Materials today. Bio · 2026Review
- Facile Access to IDT-Based Acceptor via Direct C-H Arylation and Its Exploration in Binary and Ternary Organic Solar Cells.Chemistry, an Asian journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photocatalytic therapy holds great prospects in high-performance tumor treatment owing to its advantages of noninvasiveness and oxygen nonreliance. However, there is still a lack of ideal photocatalyst materials that respond to near-infrared (NIR) light, especially with organelle-specific features. Here, a mitochondria-biomimetic organic semiconductor photocatalyst was designed for NIR-activatable photocatalytic immunotherapy of recurrent and metastatic tumor. With biomimetic of mitochondrial membrane, a NIR-responsive conjugated polymer YBSe-SS was prepared into biomimetic nano-photocatalysts (Mito-NPs). Upon NIR-light irradiation, the Mito-NPs achieved effective photocatalytic oxidation of reduced nicotinamide adenine dinucleotide and mitochondria dysfunction, benefiting from the mitochondria-targeted performance. Also, relatively high multiphototheranostics were demonstrated by the Mito-NPs. Subsequently, with Mito-NP-regulated mitochondrial function and metabolism, the in vivo experiments proved that the photocatalytic Mito-NPs combined with immune checkpoint therapy achieved photocatalytic immunotherapy for suppressing primary and pulmonary metastasis of osteosarcoma. This work offers a practical paradigm for NIR-activatable organic photocatalytic materials for high-performance tumor therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.